化合物 T11410L | 1215085-92-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 化合物 T11410L
• 英文名称: GLPG0492
• 英文别名: (S)-(-)-4-[2,5-dioxo-4-(hydroxymethyl)-3-methyl-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile；4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile；G 100192；GLPG0942；(S)-4-[2,5-dioxo-4-hydroxymethyl-3-methyl-4-phenylimidazolidin-1-yl]-2-trifluoromethylbenzonitrile；Glpg-0492
• CAS: 1215085-92-9
• 化学式: C₁₉H₁₄F₃N₃O₃
• 分子量: 389.334
• InChiKey: VAJGULUVTFDTAS-GOSISDBHSA-N

物化性质

• 熔点：
  66 - 71°C
• 沸点：
  544.0±60.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、乙醇（轻微、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  84.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  化合物 T11410L 、 氯磷酸二乙酯 在 吡啶 作用下， 反应 48.0h， 生成 (S)-[1-(4-cyano-3-trifluoromethylphenyl)-2,5-dioxo-3-methyl-4-phenylimidazolidin-4-yl]methyl diethyl phosphate
  参考文献：
  名称：

  [EN] NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
  [FR] NOUVEAUX COMPOSÉS D'IMIDAZOLIDINE EN TANT QUE MODULATEURS DU RÉCEPTEUR D'ANDROGÈNE

  摘要：

  揭示了具有以下公式表示的新化合物：其中X、R1、R2a、R2b、R2c、R3a、R3b、R4a、R4b、R4c和ml如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如消瘦、骨质疏松症、肌肉减少、性欲下降和/或性功能障碍。

  公开号：

  WO2010029119A1
• 作为产物：
  描述：

  4-[2,5-dioxo-4-(hydroxymethyl)-3-methyl-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 以48的产率得到化合物 T11410L
  参考文献：
  名称：

  J. Med. Chem. 2012, 55, 8236-8247

  摘要：

  DOI：

文献信息

• NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
  申请人：Nique François

  公开号：US20100113547A1

  公开（公告）日：2010-05-06

  Novel compounds are disclosed that have a Formula represented by the following: wherein X, R 1 , R 2a , R 2b , R 2c , R 3a R 3b , R 4a , R 4b , R 4c , and m1 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cachexia, osteoporosis, sarcopenia, a decline in libido and/or sexual dysfunction.

  披露了一种具有以下式子表示的新型化合物：其中X、R1、R2a、R2b、R2c、R3aR3b、R4a、R4b、R4c和m1如本文所述。这些化合物可以制备为药物组成物，并可用于预防和治疗哺乳动物包括人类的各种疾病，包括但不限于消瘦症、骨质疏松症、肌肉萎缩症、性欲下降和/或性功能障碍。
• Imidazolidine compounds as androgen receptor modulators
  申请人：Galapagos NV

  公开号：US07968581B2

  公开（公告）日：2011-06-28

  Novel compounds are disclosed that have a Formula represented by the following: wherein X, R1, R2a, R2b, R2c, R3a R3b, R4a, R4b, R4c, and m1 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cachexia, osteoporosis, sarcopenia, a decline in libido and/or sexual dysfunction.

  披露了具有以下公式表示的新化合物：其中X、R1、R2a、R2b、R2c、R3a、R3b、R4a、R4b、R4c和m1的描述如本文所述。这些化合物可以制备成药物组合物，并可用于预防和治疗哺乳动物，包括人类的各种疾病，例如消瘦症、骨质疏松症、肌肉萎缩症、性欲下降和/或性功能障碍等。
• Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator
  作者：François Nique、Séverine Hebbe、Nicolas Triballeau、Christophe Peixoto、Jean-Michel Lefrançois、Hélène Jary、Luke Alvey、Murielle Manioc、Christopher Housseman、Hugo Klaassen、Kris Van Beeck、Denis Guédin、Florence Namour、Dominque Minet、Ellen Van der Aar、Jean Feyen、Stephen Fletcher、Roland Blanqué、Catherine Robin-Jagerschmidt、Pierre Deprez

  DOI：10.1021/jm300281x

  日期：2012.10.11

  Structural modification performed on a 4-methyl-4-(4-hydroxyphenyphyl)hydantoin series is described which resulted in the development of a new series of 4-(hydroxymethyl)diarylhydantoin analogues as potent, partial agonists of the human androgen receptor. This led to the identification of (S)-(-)-4-(4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile ((S)-(-)-18a, GLPG0492) evaluated in vivo in a classical model of orchidectomized rat. In this model, (-)-18a exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing. (-)-18a has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials.
• METHODS FOR TREATMENT OF MUSCULAR DYSTROPHIES
  申请人：Bush Ernest D.

  公开号：US20160250188A1

  公开（公告）日：2016-09-01

  The present invention relates to, inter alia, treatment of muscle dystrophy (e.g., Duchenne Muscular Dystrophy), for example, using a composition, e.g., a composition comprising Compound (I), or a pharmaceutically acceptable salt, prodrug or metabolite thereof.
• US7968581B2
  申请人：——

  公开号：US7968581B2

  公开（公告）日：2011-06-28